奥西默蒂尼布和第一代和第二代EGFR-TKI之间的安全信号检测差异:使用自发报告系统进行药监测研究
Tomoya Sugimoto1,2, Yoshihiro Noguchi3, Rikuto Masuda3
1Laboratory of Advanced Medical Care Community Pharmacy, Gifu Pharmaceutical University, Gifu, Japan, tomoyas1119@gmail.com.
Oncology
|September 25, 2025
概括
与其他EGFR-TKI相比,奥西默提尼布显示心脏毒性和骨髓抑制的安全信号增加. 间歇性肺炎并不是一个显著的风险,但由于潜在的报告差异,建议谨慎.
科学领域:
- 药物监督 药物监督 药物监督
- 在瘤学瘤学.
- 药品安全 药品安全
背景情况:
- 奥西默提尼布和其他表皮生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 用于癌症治疗.
- 了解这些药物的安全性概况和不良事件检测趋势对于患者安全至关重要.
研究的目的:
- 将 osimertinib 的安全信号检测趋势与其他 EGFR-TKI 进行比较.
- 为了确定与 osimertinib.com 相关的潜在风险和不良事件.
主要方法:
- 利用了来自日本药物不良事件报告 (JADER) 和FDA不良事件报告系统 (FAERS) 的数据进行火山情节分析.
- 使用医学监管活动词典 (MedDRA) 高级术语 (HLT) 标准化的不良事件报告.
- 对 osimertinib,gefitinib,erlotinib 和 afatinib 的安全信号进行比较.
主要成果:
- 与某些EGFR-TKI相比,奥西默提尼布在JADER (24) 和FAERS (7) 中显示了更多的安全信号.
- 在JADER.中,经常报告的奥西默提尼布不良反应包括"中毒和毒性"和"心力衰竭".
- 在FAERS中",死亡和突然死亡"和"大髓抑郁和低可塑性贫血症"主要是针对 osimertinib.
结论:
- 证实了心脏毒性,骨髓抑制和贫血的增加报告与 osimertinib.
- 间歇性肺炎没有被确定为一个重要的安全信号.
- 强调注意报告的不良事件率与真实发生率之间的潜在差异.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.4K
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
5.5K
相关概念视频
01:19Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
01:16Therapeutic Drug Monitoring: Overview and Classification
309
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
309